Bo Rode Hansen, President and CEO, comments
“It is with pleasure that we report on our activities for the first quarter of 2022. It has been a good start to the year with solid operations, continued execution of our strategy and implementation of our plans. I am looking at a company “punching above its weight” in several ways.”
Key Figures & Highlights
|TDKK||Q1 2022||Q1 2021||FY 2021|
|Net finance income/cost||-251||-1,350||-1,846|
|Loss before tax||-16,563||-11,254||-57,213|
|Earnings per share (EPS)||-0.40||-0.28||-1.61|
|Shares outstanding, ending||32,135,544||21,293,396||32,135,544|
Highlights during Q1 2022
- On January 12, Scandion Oncology announced that Mads Kronborg, bringing more than a decade of corporate communication and investor relations experience in the global life-science industry, will now help plan and drive its external communication as Head of External Communication.
- On January 18, Scandion Oncology announced that data with the Company’s lead compound SCO-101 as combination therapy in patients with metastatic colorectal cancer was accepted for poster presentation at the ASCO Gastrointestinal Cancers Symposium.
- On February 2, Scandion Oncology announced approval from the German and Spanish regulatory authorities to expand part 2 of the CORIST Phase II study to Germany and Spain.
Highlights after the end of the period
- On May 11, Scandion Oncology enhances management and clinical development function with appointment of global executive as Chief Medical Officer. Dr. Alfredo Zurlo brings decades of experience from clinical development in oncology.
The interim report Q1 2022 is available on the Company’s website: www.scandiononcology.com.
Audiocast today, May 19 at 10:00 am CET
Today at 10:00, Scandion Oncology’s executive management will host a webcast and conference call presenting the results and a company update.
At the end of the presentation there will be a Q&A session.
Access to the event can be obtained as follows:
Webcast replay will be available at www.scandiononcology.com in the Investors section and at www.financialhearings.com
For further information please contact:
Mads Kronborg, Head of External Communication
Phone: +45 6051 4955
The information was provided by the contact person above for publication on May 19, 2022, at 08.30 CET.
Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.
Globally, close to 10 million patients die every year from treatment resistant cancers, and our medicines are relevant in several different cancers as oral add-on drugs to existing market leading therapies. That makes both our medical and commercial potential significant.
Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL).
Västra Hamnen Corporate Finance is the Company’s certified advisor on Nasdaq First North Growth Market and can be reached at firstname.lastname@example.org or +46 (0) 40 200 250.